Newsfeeds Archive - Spark Newswire

2 minute read

Reported Earlier, “WHO ‘Very Worried’ About Spread Of Mpox In DRC” – Reuters News

December 8, 1:31 PM

https://www.reuters.com/business/healthcare-pharmaceuticals/who-very-worried-about-spread-mpox-drc-2023-12-08/?taid=65734f21df0b0e0001648213&utm_campaign=trueanthem&utm_medium=trueanthem&utm_source=twitterThe

AEMD

29 minute read

Earnings

Earnings Scheduled For November 2, 2023

By Benzinga Insights

November 2, 4:56 AM

Companies Reporting Before The Bell • AudioCodes (NASDAQ:AUDC) is estimated to report quarterly earnings at $0.18 per share on revenue of $61.52 million.

AAPL

1 minute read

Earnings

Earnings Outlook For Chimerix

By Benzinga Insights

November 1, 3:01 PM

Chimerix (NASDAQ:CMRX) is set to give its latest quarterly earnings report on Thursday, 2023-11-02. Here’s what investors need…

CMRX

2 minute read

NetSol Technologies And 2 Other Stocks Under $2 Insiders Are Buying

By Lisa Levin

September 27, 9:14 AM

The Dow Jones closed lower by around 388 points on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

ALZN

1 minute read

News

Overview Of Value Stocks In The Healthcare Sector

By Benzinga Insights

September 18, 10:43 AM

The Meaning Behind Value Stocks A value stock is traditionally defined in terms of how investors in the…

ACOR

3 minute read

FDA
News

CHP Investigates Two Confirmed Mpox Cases

By Benzinga Newsdesk

August 18, 9:00 AM

The Centre for Health Protection (CHP) of the Department of Health (DH) said today (August 18) that it is investigating two confirmed Mpox (also known as Monkeypox) cases, and urged the public to heighten vigilance

AEMD

2 minute read

Analyst Ratings

4 Analysts Have This to Say About Chimerix

By Benzinga Insights

August 17, 4:00 PM

Chimerix (NASDAQ:CMRX) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish…

CMRX

3 minute read

Chimerix Announces Data Highlighting Clinical Efficacy And Molecular Mechanisms Of Response To ONC201 Treatment Of H3 K27M-Mutant Diffuse Midline Gliomas Published In “Cancer Discovery”

By Happy Mohamed

August 16, 10:07 AM

Patients Treated with ONC201 Demonstrated Median Overall Survival (mOS) of 21.7 Months in the Front-Line Setting, Post Radiation, Versus 12 Months mOS Historical Control ONC201 Treatment Disrupts Key Metabolic

CMRX